Roche has agreed to a $5.3 billion deal with Zealand Pharma to develop the obesity drug candidate petrelintide, including a fixed-dose combination with Roche’s CT-388, aiming to compete in the weight loss drug market. Zealand Pharma will receive $1.65 billion upfront and potential milestone payments, with shares of both companies rising after the announcement. The partnership will see Roche and Zealand jointly commercialize petrelintide in the U.S. and Europe, sharing profits and losses equally, while Roche will have exclusive commercialization rights in the rest of the world.
Full Article
Tim Dolighan cartoon, March 13, 2025
Tim Dolighan's cartoon from March 13, 2025, is the subject of this article. The video failed to load, but viewers are encouraged to refresh their browsers or check out other videos from the team. The content of the cartoon is not provided in the summary. Full Article
Read more